Search

Your search keyword '"Peccatori J."' showing total 620 results
Start Over Author "Peccatori J."
620 results on '"Peccatori J."'

5. Quantitative polymerase chain reaction-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: Results from the KIM-PB prospective study

Author

Gambacorta, V, Parolini, R, Xue, E, Greco, R, Bouwmans, E, Toffalori, C, Giglio, F, Assanelli, A, Stanghellini, M, Ambrosi, A, Mazzi, B, Mulder, W, Corti, C, Peccatori, J, Ciceri, F, Vago, L, Gambacorta V., Parolini R., Xue E., Greco R., Bouwmans E. E., Toffalori C., Giglio F., Assanelli A., Stanghellini M. T. L., Ambrosi A., Mazzi B., Mulder W., Corti C., Peccatori J., Ciceri F., Vago L., Gambacorta, V, Parolini, R, Xue, E, Greco, R, Bouwmans, E, Toffalori, C, Giglio, F, Assanelli, A, Stanghellini, M, Ambrosi, A, Mazzi, B, Mulder, W, Corti, C, Peccatori, J, Ciceri, F, Vago, L, Gambacorta V., Parolini R., Xue E., Greco R., Bouwmans E. E., Toffalori C., Giglio F., Assanelli A., Stanghellini M. T. L., Ambrosi A., Mazzi B., Mulder W., Corti C., Peccatori J., Ciceri F., and Vago L.

Published
2021

7. A Novel Assay in Whole Blood Demonstrates Restoration of Mitochondrial Activity in Phagocytes After Successful HSCT in Hyperinflamed X-Linked Chronic Granulomatous Disease

Author

Migliavacca, M., Basso Ricci, L., Farinelli, G., Calbi, V., Tucci, F., Barzaghi, F., Ferrua, F., Cicalese, M. P., Darin, S., Barzaghi, L. R., Giglio, F., Peccatori, J., Fumagalli, F., Nicoletti, R., Giannelli, S., Sartirana, C., Bandiera, A., Esposito, M., Milani, R., Mazzi, B., Finocchi, A., Marktel, S., Assanelli, A., Locatelli, Franco, Ciceri, F., Aiuti, A., Bernardo, M. E., Locatelli F. (ORCID:0000-0002-7976-3654), Migliavacca, M., Basso Ricci, L., Farinelli, G., Calbi, V., Tucci, F., Barzaghi, F., Ferrua, F., Cicalese, M. P., Darin, S., Barzaghi, L. R., Giglio, F., Peccatori, J., Fumagalli, F., Nicoletti, R., Giannelli, S., Sartirana, C., Bandiera, A., Esposito, M., Milani, R., Mazzi, B., Finocchi, A., Marktel, S., Assanelli, A., Locatelli, Franco, Ciceri, F., Aiuti, A., Bernardo, M. E., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

X-linked chronic granulomatous disease is a rare disease caused by mutations in the CYBB gene. While more extensive knowledge is available on genetics, pathogenesis, and possible therapeutic options, mitochondrial activity and its implications on patient monitoring are still not well-characterized. We have developed a novel protocol to study mitochondrial activity on whole blood of XCGD patients before and after transplantation, as well as on XCGD carriers. Here we present results of these analyses and of the restoration of mitochondrial activity in hyperinflamed X-linked Chronic Granulomatous Disease after hematopoietic stem cell transplantation. Moreover, we show a strong direct correlation between mitochondrial activity, chimerism, and DHR monitored before and after transplantation and in XCGD carriers. In conclusion, based on these findings, we suggest testing this new ready-to-use marker to better characterize patients before and after treatment and to investigate disease expression in carriers.

Published
2022

8. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01

Author

Bonifazi, F., Pavoni, C., Peccatori, J., Giglio, F., Arpinati, M., Busca, A., Bernasconi, P., Grassi, A., Iori, A. P., Patriarca, F., Brunello, L., Di Grazia, C., Carella, A. M., Cilloni, D., Picardi, A., Proia, A., Santarone, S., Sorasio, R., Carluccio, P., Chiusolo, Patrizia, Cupri, A., Luppi, M., Nozzoli, C., Baronciani, D., Casini, M., Grillo, G., Musso, M., Onida, F., Palazzo, G., Parma, M., Tringali, S., Vacca, A., Vallisa, D., Sacchi, N., Oldani, E., Masciulli, A., Gheorghiu, A., Girmenia, C., Martino, M., Bruno, B., Rambaldi, A., Ciceri, F., Chiusolo P. (ORCID:0000-0002-1355-1587), Bonifazi, F., Pavoni, C., Peccatori, J., Giglio, F., Arpinati, M., Busca, A., Bernasconi, P., Grassi, A., Iori, A. P., Patriarca, F., Brunello, L., Di Grazia, C., Carella, A. M., Cilloni, D., Picardi, A., Proia, A., Santarone, S., Sorasio, R., Carluccio, P., Chiusolo, Patrizia, Cupri, A., Luppi, M., Nozzoli, C., Baronciani, D., Casini, M., Grillo, G., Musso, M., Onida, F., Palazzo, G., Parma, M., Tringali, S., Vacca, A., Vallisa, D., Sacchi, N., Oldani, E., Masciulli, A., Gheorghiu, A., Girmenia, C., Martino, M., Bruno, B., Rambaldi, A., Ciceri, F., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

The outcome of refractory/relapsed (R/R) acute leukemias is still dismal and their treatment represents an unmet clinical need. However, allogeneic transplantation (allo-HSCT) remains the only potentially curative approach in this setting. A prospective study (GANDALF-01, NCT01814488; EUDRACT:2012-004008-37) on transplantation with alternative donors had been run by GITMO using a homogeneous myeloablative conditioning regimen with busulfan, thiotepa and fludarabine while GVHD prophylaxis was stratified by donor type. The study enrolled 101 patients; 90 found an alternative donor and 87 ultimately underwent allo-HSCT. Two-year overall survival of the entire and of the transplant population (primary endpoint) were 19% and 22%, without significant differences according to disease, donor type and disease history (relapsed vs refractory patients). Two-year progression-free survival was 19% and 17% respectively. The cumulative incidences of relapse and non-relapse mortality were 49% and 33% at two years. Acute grade II-IV and chronic GVHD occurred in 23 and 10 patients. Dose intensification with a myeloablative two-alkylating regimen as sole strategy for transplanting R/R acute leukemia does seem neither to improve the outcome nor to control disease relapse. A pre-planned relapse prevention should be included in the transplant strategy in this patient population.

Published
2022

9. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

Author

Crucitti, L, Crocchiolo, R, Toffalori, C, Mazzi, B, Greco, R, Signori, A, Sizzano, F, Chiesa, L, Zino, E, Lupo Stanghellini, M T, Assanelli, A, Carrabba, M G, Marktel, S, Marcatti, M, Bordignon, C, Corti, C, Bernardi, M, Peccatori, J, Bonini, C, Fleischhauer, K, Ciceri, F, and Vago, L

Published
2015
Full Text
View/download PDF

10. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Author

Peccatori, J, Forcina, A, Clerici, D, Crocchiolo, R, Vago, L, Stanghellini, M T L, Noviello, M, Messina, C, Crotta, A, Assanelli, A, Marktel, S, Olek, S, Mastaglio, S, Giglio, F, Crucitti, L, Lorusso, A, Guggiari, E, Lunghi, F, Carrabba, M, Tassara, M, Battaglia, M, Ferraro, A, Carbone, M R, Oliveira, G, Roncarolo, M G, Rossini, S, Bernardi, M, Corti, C, Marcatti, M, Patriarca, F, Zecca, M, Locatelli, F, Bordignon, C, Fleischhauer, K, Bondanza, A, Bonini, C, and Ciceri, F

Published
2015
Full Text
View/download PDF

12. Correction to: Refractory anti‑NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review (Journal of Neurology, (2020), 267, 8, (2462-2468), 10.1007/s00415-020-09988-w)

Author

Lazzarin S. M., Vabanesi M., Cecchetti G., Fazio R., Fanelli G. F., Volonte M. A., Genchi A., Giordano A., Martinelli V., Colombo S., Beccaria P., Mucci M., Peccatori J., Filippi M., Minicucci F., Lazzarin, S. M., Vabanesi, M., Cecchetti, G., Fazio, R., Fanelli, G. F., Volonte, M. A., Genchi, A., Giordano, A., Martinelli, V., Colombo, S., Beccaria, P., Mucci, M., Peccatori, J., Filippi, M., and Minicucci, F.

Abstract

The authors would like to correct some errors in the publication of the original article. The corrected and updated details are given below for your reading.

Published
2021

13. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT

Author

Noviello, M, Manfredi, F, Ruggiero, E, Perini, T, Oliveira, G, Cortesi, F, De Simone, P, Toffalori, C, Gambacorta, V, Greco, R, Peccatori, J, Casucci, M, Casorati, G, Dellabona, P, Onozawa, M, Teshima, T, Griffioen, M, Halkes, C, Falkenburg, J, Stolzel, F, Altmann, H, Bornhauser, M, Waterhouse, M, Zeiser, R, Finke, J, Cieri, N, Bondanza, A, Vago, L, Ciceri, F, Bonini, C, Noviello M., Manfredi F., Ruggiero E., Perini T., Oliveira G., Cortesi F., De Simone P., Toffalori C., Gambacorta V., Greco R., Peccatori J., Casucci M., Casorati G., Dellabona P., Onozawa M., Teshima T., Griffioen M., Halkes C. J. M., Falkenburg J. H. F., Stolzel F., Altmann H., Bornhauser M., Waterhouse M., Zeiser R., Finke J., Cieri N., Bondanza A., Vago L., Ciceri F., Bonini C., Noviello, M, Manfredi, F, Ruggiero, E, Perini, T, Oliveira, G, Cortesi, F, De Simone, P, Toffalori, C, Gambacorta, V, Greco, R, Peccatori, J, Casucci, M, Casorati, G, Dellabona, P, Onozawa, M, Teshima, T, Griffioen, M, Halkes, C, Falkenburg, J, Stolzel, F, Altmann, H, Bornhauser, M, Waterhouse, M, Zeiser, R, Finke, J, Cieri, N, Bondanza, A, Vago, L, Ciceri, F, Bonini, C, Noviello M., Manfredi F., Ruggiero E., Perini T., Oliveira G., Cortesi F., De Simone P., Toffalori C., Gambacorta V., Greco R., Peccatori J., Casucci M., Casorati G., Dellabona P., Onozawa M., Teshima T., Griffioen M., Halkes C. J. M., Falkenburg J. H. F., Stolzel F., Altmann H., Bornhauser M., Waterhouse M., Zeiser R., Finke J., Cieri N., Bondanza A., Vago L., Ciceri F., and Bonini C.

Abstract

The major cause of death after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for acute myeloid leukemia (AML) is disease relapse. We investigated the expression of Inhibitory Receptors (IR; PD-1/CTLA-4/TIM-3/LAG-3/2B4/KLRG1/GITR) on T cells infiltrating the bone marrow (BM) of 32 AML patients relapsing (median 251 days) or maintaining complete remission (CR; median 1 year) after HSCT. A higher proportion of early-differentiated Memory Stem (T SCM ) and Central Memory BM-T cells express multiple IR in relapsing patients than in CR patients. Exhausted BM-T cells at relapse display a restricted TCR repertoire, impaired effector functions and leukemia-reactive specificities. In 57 patients, early detection of severely exhausted (PD-1 + Eomes + T-bet − ) BM-T SCM predicts relapse. Accordingly, leukemia-specific T cells in patients prone to relapse display exhaustion markers, absent in patients maintaining long-term CR. These results highlight a wide, though reversible, immunological dysfunction in the BM of AML patients relapsing after HSCT and suggest new therapeutic opportunities for the disease.

Published
2019

25. VENTILATION HETEROGENEITY OF PERIPHERAL AIRWAYS (SACIN*VT) ASSESSED BY NITROGEN MULTIPLE BREATH WASHOUT (N2-MBW) IS AN ACCURATE AND SENSITIVE MARKER OF BRONCHIOLITIS OBLITERANS - THE SAN RAFFAELE EXPERIENCE IN HSCT SETTING: PH-P360

Author

De Giacomi, F., Orsini, A., Guggiari, E., Corti, C., Calcaterra, B., Forcina, A., Perini, T., Piemontese, S., Pavesi, F., Levati, G., Milani, R., Peccatori, J., Bernardi, M., Assanelli, A., Bonini, C., Ciceri, F., Cremona, G., and Lupo-Stanghellini, M.

Published
2014

31. T CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOLLOWED BY ADD-BACKS OF SUICIDE-GENE MODIFIED DONOR T-CELLS OFFERS LONG TERM SURVIVAL FREE OF IMMUNE SUPPRESSION TREATMENT: A 7 YEARS FOLLOW-UP IN 56 PATIENTS: PH-O084

Author

Lupo-Stanghellini, M. T., Greco, R., Oliveira, G., Peccatori, J., Marcatti, M., Guggiari, E., Lunghi, F., Marktel, S., Giglio, F., Bondanza, A., Malerba, A., Trinca, S., Corti, C., Bernardi, M., Lambiase, A., Bordignon, C., Bonini, C., and Ciceri, F.

Published
2014

38. Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial

Author

Peccatori, J., Mastaglio, S., Giglio, F., Greco, R., Crocchiolo, R., Patriarca, F., Forno, B., Deola, S., Assanelli, A., Lupo Stanghellini, M. T., Marcatti, M., Zecca, M., Cortelazzo, S., Fanin, R., Fagioli, F., Locatelli, Franco, Ciceri, F., Locatelli F. (ORCID:0000-0002-7976-3654), Peccatori, J., Mastaglio, S., Giglio, F., Greco, R., Crocchiolo, R., Patriarca, F., Forno, B., Deola, S., Assanelli, A., Lupo Stanghellini, M. T., Marcatti, M., Zecca, M., Cortelazzo, S., Fanin, R., Fagioli, F., Locatelli, Franco, Ciceri, F., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be curative for patients with hematologic malignancies. The ideal conditioning regimen before allo-HSCT has not been established. We conducted a Phase II study to evaluate the tolerability and efficacy of clofarabine and treosulfan as conditioning regimen before allo-HSCT. The primary objective was to evaluate the cumulative incidence of nonrelapse mortality (NRM) on day +100. Forty-four patients (36 with acute myelogenous leukemia, 5 with acute lymphoblastic leukemia, 3 with myelodysplastic syndromes) were enrolled. The median patient age was 47 years, and the median duration of follow-up was 27 months. The conditioning regimen was based on clofarabine 40 mg/m2 (days -6 to -2) and treosulfan 14 g/m2 (days -6 to -4). Allogeneic hematopoietic stem cells were derived from a sibling (n = 22) or a well-matched unrelated donor (n = 22). Graft-versus-host disease (GVHD) prophylaxis consisted of antithymocyte globulin, rituximab, cyclosporine, and a short-course of methotrexate. The regimen allowed for rapid engraftment and a 100-day NRM of 18%, due mainly to bacterial infections. The incidences of grade II-IV acute GVHD and chronic GVHD were 16% and 19%, respectively. The rates of overall survival (OS), progression-free survival, and relapse at 2 years were 51%, 31%, and 50%, respectively. Significantly different outcomes were observed between patients with low-intermediate and patients with high-very high Disease Risk Index (DRI) scores (1-year OS, 78% and 24%, respectively). Our findings show that the use of treosulfan and clofarabine as a conditioning regimen for allo-HSCT is feasible, with a 78% 1-year OS in patients with a low-intermediate DRI score. However, 1-year NRM was 18%, and despite the intensified conditioning regimen, relapse incidence remains a major issue in patients with poor prognostic risk factors.

Published
2020

45. Treosulfan-based conditioning regimen allows an early full donor chimerism after related and unrelated transplant with low toxicity. Results from a prospective single-centre study: P972

Author

Lorusso, A., Crotta, A., Messina, C., Ruggeri, A., Forno, B., Marcatti, M., Clerici, D., Lupo Stanghellini, M. T., Giglio, F., Mastaglio, S., Forcina, A., Malato, S., Lunghi, F., Assanelli, A., Gattillo, S., Ronchi, P., Fleischhauer, K., Bernardi, M., Corti, C., Ciceri, F., and Peccatori, J.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results